{"pmid":32418299,"title":"The COVID-19 chemoprophylactic conundrum - Are we limiting available resources?","text":["The COVID-19 chemoprophylactic conundrum - Are we limiting available resources?","Dermatol Ther","Sharma, Aseem","Mhatre, Madhulika","Goldust, Mohamad","Jindal, Veenu","Singla, Palvi","32418299"],"journal":"Dermatol Ther","authors":["Sharma, Aseem","Mhatre, Madhulika","Goldust, Mohamad","Jindal, Veenu","Singla, Palvi"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418299","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dth.13607","keywords":["covid-19","sars-cov-2","healthcare workers","hydroxychloroquine","pandemic","repositioning","survey"],"topics":["Treatment"],"weight":1,"_version_":1667058206756569088,"score":9.490897,"similar":[{"pmid":32316270,"title":"COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.","text":["COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.","The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona alkaloids, these chiral antimalarials are currently in use as the racemate. Besides the ethical concern related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential detrimental cardiac effects of these drugs should also be considered. In principle, the safety profile might be ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place of the racemate.","Molecules","Lentini, Giovanni","Cavalluzzi, Maria Maddalena","Habtemariam, Solomon","32316270"],"abstract":["The desperate need to find drugs for COVID-19 has indicated repurposing strategies as our quickest way to obtain efficacious medicines. One of the options under investigation is the old antimalarial drug, chloroquine, and its analog, hydroxychloroquine. Developed as synthetic succedanea of cinchona alkaloids, these chiral antimalarials are currently in use as the racemate. Besides the ethical concern related to accelerated large-scale clinical trials of drugs with unproven efficacy, the known potential detrimental cardiac effects of these drugs should also be considered. In principle, the safety profile might be ameliorated by using chloroquine/hydroxychloroquine single enantiomers in place of the racemate."],"journal":"Molecules","authors":["Lentini, Giovanni","Cavalluzzi, Maria Maddalena","Habtemariam, Solomon"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32316270","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3390/molecules25081834","keywords":["2019-ncov","covid-19","ebola","mers","sars","sars-cov-2","chiral switch","hydroxychloroquine","repositioning"],"e_drugs":["Hydroxychloroquine","Chloroquine","Cinchona Alkaloids"],"topics":["Treatment"],"weight":1,"_version_":1666138493737238528,"score":72.768295},{"pmid":32440724,"title":"Impact of COVID-19 Outbreak on Healthcare Workers in Italy: Results from a National E-Survey.","text":["Impact of COVID-19 Outbreak on Healthcare Workers in Italy: Results from a National E-Survey.","Italy has been the first-hit European country to face the outbreak of coronavirus disease 2019 (COVID-19). Aim of this survey was to assess in depth the impact of the outbreak on healthcare workers (HCW). A 40-item online survey was disseminated via social media inviting Italian HCW, with questions exploring demographics, health status and work environment of respondents. A total of 527 were invited to take part in March 2020, of whom 74% (n = 388) responded to the survey. Of these, 235 (61%) were women. HCW were mostly physicians (74%), from high-prevalence regions (52%). 25% experienced typical symptoms during the last 14 days prior to survey completion, with only 45% of them being tested for COVID-19. Among the tested population, 18 (18%) resulted positive for COVID-19, with 33% being asymptomatic. Only 22% of HCW considered personal protective equipment adequate for quality and quantity. Females and respondents working in high-risk sectors were more likely to rate psychological support as useful (OR, 1.78 [CI 95% 1.14-2.78] P = 0.012, and 2.02 [1.12-3.65] P = 0.020, respectively) and workload as increased (mean increase, 0.38 [0.06-0.69] P = 0.018; and 0.54 [0.16-0.92] P = 0.005, respectively). The insights from this survey may help authorities in countries where COVID-19 epidemic has not yet broken out. Management strategies should be promptly undertaken in order to enhance safety and optimise resource allocation.","J Community Health","Felice, Carla","Di Tanna, Gian Luca","Zanus, Giacomo","Grossi, Ugo","32440724"],"abstract":["Italy has been the first-hit European country to face the outbreak of coronavirus disease 2019 (COVID-19). Aim of this survey was to assess in depth the impact of the outbreak on healthcare workers (HCW). A 40-item online survey was disseminated via social media inviting Italian HCW, with questions exploring demographics, health status and work environment of respondents. A total of 527 were invited to take part in March 2020, of whom 74% (n = 388) responded to the survey. Of these, 235 (61%) were women. HCW were mostly physicians (74%), from high-prevalence regions (52%). 25% experienced typical symptoms during the last 14 days prior to survey completion, with only 45% of them being tested for COVID-19. Among the tested population, 18 (18%) resulted positive for COVID-19, with 33% being asymptomatic. Only 22% of HCW considered personal protective equipment adequate for quality and quantity. Females and respondents working in high-risk sectors were more likely to rate psychological support as useful (OR, 1.78 [CI 95% 1.14-2.78] P = 0.012, and 2.02 [1.12-3.65] P = 0.020, respectively) and workload as increased (mean increase, 0.38 [0.06-0.69] P = 0.018; and 0.54 [0.16-0.92] P = 0.005, respectively). The insights from this survey may help authorities in countries where COVID-19 epidemic has not yet broken out. Management strategies should be promptly undertaken in order to enhance safety and optimise resource allocation."],"journal":"J Community Health","authors":["Felice, Carla","Di Tanna, Gian Luca","Zanus, Giacomo","Grossi, Ugo"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440724","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s10900-020-00845-5","keywords":["covid-19","coronavirus","healthcare workers","personal protective equipment","sars-cov-2","survey"],"locations":["Italy","Italian","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1667535119527706624,"score":59.230556},{"pmid":32278811,"pmcid":"PMC7194941","title":"Drug repositioning is an alternative for the treatment of coronavirus COVID-19.","text":["Drug repositioning is an alternative for the treatment of coronavirus COVID-19.","Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.","Int J Antimicrob Agents","Serafin, Marissa B","Bottega, Angelita","Foletto, Vitoria S","da Rosa, Tacieli F","Horner, Andreas","Horner, Rosmari","32278811"],"abstract":["Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease."],"journal":"Int J Antimicrob Agents","authors":["Serafin, Marissa B","Bottega, Angelita","Foletto, Vitoria S","da Rosa, Tacieli F","Horner, Andreas","Horner, Rosmari"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278811","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ijantimicag.2020.105969","keywords":["covid-19","repositioning","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138491559346177,"score":57.322258},{"pmid":32437242,"title":"Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy.","text":["Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy.","Aim: To assess which and when measures were applied to reduce coronavirus disease (COVID-19) spreads have been applied in medical oncology departments. Materials & methods: We surveyed all medical oncology departments from the Italian Emilia Romagna region via a multidomain questionnaire. The questions covered items on patients, healthcare workers, risk reduction measure and clinical trials. Results: A total of 12 centers involving 861 healthcare members joined the survey. The measures applied to patients and health workers partially converged in all the departments while major divergences were found in the clinical trials domain. High rate of COVID-19 infection occurred among medical doctors (21/208, 10.1%) and social care workers (13/110, 11.8%). Rate of infection among nurses was 5.7% (24/418). Conclusion: All measures able to reduce risk of COVID-19 infection must be applied in medical oncology departments. Early introduction of risk reduction measures may be a critical issue.","Future Oncol","Brandes, Alba A","Ardizzoni, Andrea","Artioli, Fabrizio","Cappuzzo, Federico","Cavanna, Luigi","Frassineti, Giovanni Luca","Frassoldati, Antonio","Leonardi, Francesco","Longo, Giuseppe","Maestri, Antonio","Tassinari, Davide","Franceschi, Enrico","Nunno, Vincenzo Di","Pinto, Carmine","32437242"],"abstract":["Aim: To assess which and when measures were applied to reduce coronavirus disease (COVID-19) spreads have been applied in medical oncology departments. Materials & methods: We surveyed all medical oncology departments from the Italian Emilia Romagna region via a multidomain questionnaire. The questions covered items on patients, healthcare workers, risk reduction measure and clinical trials. Results: A total of 12 centers involving 861 healthcare members joined the survey. The measures applied to patients and health workers partially converged in all the departments while major divergences were found in the clinical trials domain. High rate of COVID-19 infection occurred among medical doctors (21/208, 10.1%) and social care workers (13/110, 11.8%). Rate of infection among nurses was 5.7% (24/418). Conclusion: All measures able to reduce risk of COVID-19 infection must be applied in medical oncology departments. Early introduction of risk reduction measures may be a critical issue."],"journal":"Future Oncol","authors":["Brandes, Alba A","Ardizzoni, Andrea","Artioli, Fabrizio","Cappuzzo, Federico","Cavanna, Luigi","Frassineti, Giovanni Luca","Frassoldati, Antonio","Leonardi, Francesco","Longo, Giuseppe","Maestri, Antonio","Tassinari, Davide","Franceschi, Enrico","Nunno, Vincenzo Di","Pinto, Carmine"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437242","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.2217/fon-2020-0358","keywords":["covid-19","healthcare workers","medical oncology departments","oncological centresoncological patients","risk reduction","survey"],"locations":["Italian","Emilia Romagna","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1667521393716101120,"score":56.462276},{"pmid":32430617,"title":"A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).","text":["A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future.","Naunyn Schmiedebergs Arch Pharmacol","Rameshrad, Maryam","Ghafoori, Majid","Mohammadpour, Amir Hooshang","Nayeri, Mohammad Javad Dehghan","Hosseinzadeh, Hossein","32430617"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the reason for this ongoing pandemic infection diseases termed coronavirus disease 2019 (COVID-19) that has emerged since early December 2019 in Wuhan City, Hubei Province, China. In this century, it is the worst threat to international health and the economy. After 4 months of COVID-19 outbreak, there is no certain and approved medicine against it. In this public health emergency, it makes sense to investigate the possible effects of old drugs and find drug repositioning that is efficient, economical, and riskless process. Old drugs that may be effective are from different pharmacological categories, antimalarials, anthelmintics, anti-protozoal, anti-HIVs, anti-influenza, anti-hepacivirus, antineoplastics, neutralizing antibodies, immunoglobulins, and interferons. In vitro, in vivo, or preliminary trials of these drugs in the treatment of COVID-19 have been encouraging, leading to new research projects and trials to find the best drug/s. In this review, we discuss the possible mechanisms of these drugs against COVID-19. Also, it should be mentioned that in this manuscript, we discuss preliminary rationales; however, clinical trial evidence is needed to prove them. COVID-19 therapy must be based on expert clinical experience and published literature and guidelines from major health organizations. Moreover, herein, we describe current evidence that may be changed in the future."],"journal":"Naunyn Schmiedebergs Arch Pharmacol","authors":["Rameshrad, Maryam","Ghafoori, Majid","Mohammadpour, Amir Hooshang","Nayeri, Mohammad Javad Dehghan","Hosseinzadeh, Hossein"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430617","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s00210-020-01901-6","keywords":["covid-19","repositioning","sars-cov2","therapy"],"locations":["Wuhan","Hubei","China","vivo"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667342288216391680,"score":54.553974}]}